Compound glycyrrhizin dispersible tablet and preparation method thereof

Abstract

The invention pertains to the field of medicine and provides a compound glycyrrhizin dispersible tablet and a preparation method thereof, the compound glycyrrhizin dispersible tablet contains the components with the following weight percentages: 5 to 15 percent of monoammonium glycyrrhizinate, 3.5 to 10 percent of glycin, 3.5 to 10 percent of methionine, 10 to 20 percent of cross-linking PVP, 5 to 15 percent of hydroxypropyl cellulose, 35 to 45 percent of microcrystalline cellulose, 4 to 8 percent of sodium starch glycolate, 2 to 4 percent of silicon dioxide, 0.5 to 1.5 percent of magnesium stearate and 0.5 to 1.5 percent of polyvinylpyrrolidone K30. The dispersible tablet provided by the invention has the advantages of good absorption, convenient administration, high bioavailability, convenient usage, long-term combined usage, simple preparation method and so on.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a compound glycyrrhizin dispersible tablet and a preparation method thereof. Background technique [0002] The intravenous and oral preparations with glycyrrhizic acid as the main component were first developed in Japan in 1948. Because of its anti-allergic and anti-inflammatory effects, it was mainly used in the field of dermatology to treat a variety of allergic skin diseases. It was approved in 1958. Trial for the treatment of chronic hepatitis, the liver function index has been significantly improved; in 1977, Japanese liver disease experts used a strict randomized double-blind control method to verify the curative effect of compound glycyrrhizin on chronic hepatitis, and confirmed its effect on chronic hepatitis. The exact curative effect of hepatitis; in 2002, Hiromitsu Kumata reported the long-term curative effect of compound glycyrrhizin on hepatitis C. Since the compound glycyrrh...

AI Technical Summary

Problems solved by technology

[0004] At present, the compound glycyrrhizinate injection is mainly on the market. The existing problems are that it is inconvenient to use the drug, and the patient’s medication compliance is low. It is difficult for chronic patients, especially those with hepatitis, to adhere to long-term injection medication, which often leads to a decrease in the therapeutic effect.